It inhibits GLUT1 in human erythrocytes. The combination of celecoxib and genistein induces apoptosis in prostate cancer cells, with the inhibition of Glut-1 playing a key role. The combination of baicalein and genistein delays prostate cancer tumor growth by inhibiting the PI3K/AKT3 signaling pathway and reducing the number of Glut-1 transport proteins. Here, SLC2A1 is linked to prostate cancer.